Michael W. Bonney's most recent trade in Immunic Inc was a trade of 100,000 Stock Option done . Disclosure was reported to the exchange on June 29, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Immunic Inc | Michael W. Bonney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2026 | 100,000 | 100,000 | - | - | Stock Option | |
| Autolus Therapeutics PLC (ADR) | Michael W. Bonney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2026 | 47,500 | 47,500 | - | - | Share Option (Right to Buy) | |
| Autolus Therapeutics PLC (ADR) | Michael W. Bonney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2026 | 31,667 | 31,667 | - | - | Restricted Share Units | |
| Alnylam Pharma Inc | Michael W. Bonney | Director | 18 Aug 2025 | 11,250 | 0 | - | - | Stock Option (right to buy) | ||
| Alnylam Pharma Inc | Michael W. Bonney | Director | 18 Aug 2025 | 11,250 | 16,804 (0%) | 0% | 450 | 5,062,500 | Common Stock | |
| Alnylam Pharma Inc | Michael W. Bonney | Director | 18 Aug 2025 | 11,250 | 28,054 (0%) | 0% | 70.2 | 789,750 | Common Stock | |
| Alnylam Pharma Inc | Michael W. Bonney | Director | 15 May 2025 | 11,250 | 28,054 (0%) | 0% | 131.2 | 1,476,113 | Common Stock | |
| Alnylam Pharma Inc | Michael W. Bonney | Director | 15 May 2025 | 11,250 | 0 | - | - | Stock Option (right to buy) | ||
| Alnylam Pharma Inc | Michael W. Bonney | Director | 15 May 2025 | 1,728 | 18,421 (0%) | 0% | 282.8 | 488,696 | Common Stock | |
| Alnylam Pharma Inc | Michael W. Bonney | Director | 15 May 2025 | 1,617 | 16,804 (0%) | 0% | 283.8 | 458,953 | Common Stock | |
| Alnylam Pharma Inc | Michael W. Bonney | Director | 15 May 2025 | 1,263 | 22,994 (0%) | 0% | 277.2 | 350,053 | Common Stock | |
| Alnylam Pharma Inc | Michael W. Bonney | Director | 15 May 2025 | 1,239 | 21,755 (0%) | 0% | 278.0 | 344,454 | Common Stock | |
| Alnylam Pharma Inc | Michael W. Bonney | Director | 15 May 2025 | 882 | 24,558 (0%) | 0% | 273.8 | 241,448 | Common Stock | |
| Alnylam Pharma Inc | Michael W. Bonney | Director | 15 May 2025 | 802 | 20,149 (0%) | 0% | 282.0 | 226,188 | Common Stock | |
| Alnylam Pharma Inc | Michael W. Bonney | Director | 15 May 2025 | 729 | 26,776 (0%) | 0% | 268.6 | 195,780 | Common Stock | |
| Alnylam Pharma Inc | Michael W. Bonney | Director | 15 May 2025 | 660 | 25,440 (0%) | 0% | 273.2 | 180,286 | Common Stock | |
| Alnylam Pharma Inc | Michael W. Bonney | Director | 15 May 2025 | 549 | 27,505 (0%) | 0% | 267.1 | 146,660 | Common Stock | |
| Alnylam Pharma Inc | Michael W. Bonney | Director | 15 May 2025 | 432 | 21,323 (0%) | 0% | 280.0 | 120,973 | Common Stock | |
| Alnylam Pharma Inc | Michael W. Bonney | Director | 15 May 2025 | 431 | 26,100 (0%) | 0% | 271.7 | 117,094 | Common Stock | |
| Alnylam Pharma Inc | Michael W. Bonney | Director | 15 May 2025 | 372 | 20,951 (0%) | 0% | 281.1 | 104,569 | Common Stock | |
| Alnylam Pharma Inc | Michael W. Bonney | Director | 15 May 2025 | 301 | 24,257 (0%) | 0% | 275.6 | 82,965 | Common Stock | |
| Alnylam Pharma Inc | Michael W. Bonney | Director | 15 May 2025 | 245 | 26,531 (0%) | 0% | 269.8 | 66,099 | Common Stock | |
| Alnylam Pharma Inc | Michael W. Bonney | Director | 08 May 2025 | 1,558 | 1,558 | - | - | Stock Option (right to buy) | ||
| Alnylam Pharma Inc | Michael W. Bonney | Director | 08 May 2025 | 775 | 16,804 (0%) | 0% | 0 | Common Stock | ||
| Alnylam Pharma Inc | Michael W. Bonney | Director | 16 May 2024 | 5,228 | 5,228 | - | - | Stock Option (right to buy) | ||
| Alnylam Pharma Inc | W. Bonney Michael | Director | 27 Dec 2023 | 30,000 | 16,029 (0%) | 0% | 195 | 5,850,000 | Common Stock | |
| Alnylam Pharma Inc | Bonney W. Michael | Director | 27 Dec 2023 | 30,000 | 46,029 (0%) | 0% | 96.5 | 2,893,500 | Common Stock | |
| Alnylam Pharma Inc | W. Bonney Michael | Director | 27 Dec 2023 | 30,000 | 0 | - | - | Stock Option (right to buy) | ||
| Alnylam Pharma Inc | Michael W. Bonney | Director | 02 Aug 2023 | 22,477 | 22,477 (0%) | 0% | 0 | Common Stock | ||
| Alnylam Pharma Inc | Michael W. Bonney | Director | 02 Aug 2023 | 22,477 | 0 | - | - | Restricted Stock Units | ||
| Alnylam Pharma Inc | Michael W. Bonney | Director | 02 Aug 2023 | 1,714 | 17,868 (0%) | 0% | 186.0 | 318,787 | Common Stock | |
| Alnylam Pharma Inc | Michael W. Bonney | Director | 02 Aug 2023 | 1,535 | 19,582 (0%) | 0% | 184.9 | 283,806 | Common Stock | |
| Alnylam Pharma Inc | Michael W. Bonney | Director | 02 Aug 2023 | 1,389 | 16,479 (0%) | 0% | 187.0 | 259,799 | Common Stock | |
| Alnylam Pharma Inc | Michael W. Bonney | Director | 02 Aug 2023 | 560 | 21,117 (0%) | 0% | 183.8 | 102,900 | Common Stock | |
| Alnylam Pharma Inc | Michael W. Bonney | Director | 02 Aug 2023 | 500 | 21,677 (0%) | 0% | 182.5 | 91,225 | Common Stock | |
| Alnylam Pharma Inc | Michael W. Bonney | Director | 02 Aug 2023 | 450 | 16,029 (0%) | 0% | 187.7 | 84,470 | Common Stock | |
| Alnylam Pharma Inc | Michael W. Bonney | Director | 02 Aug 2023 | 300 | 22,177 (0%) | 0% | 181.1 | 54,324 | Common Stock | |
| Alnylam Pharma Inc | Michael W. Bonney | Director | 18 May 2023 | 3,454 | 3,454 | - | - | Stock Option (right to buy) | ||
| Alnylam Pharma Inc | Michael W. Bonney | Director, Executive Chair | 02 Aug 2021 | 22,477 | 22,477 | - | - | Restricted Stock Units |